Beam Therapeutics (BEAM) stock, explained like you're 5

Is Beam Therapeutics a small, medium or large cap company?

No. Beam Therapeutics is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 2.7 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Beam Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves BEAM stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? (Yahoo Finance)
• Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? (The Motley Fool)
• Beam Therapeutics (BEAM) After BEAM 302 Data And Probe Is The Undervaluation Case Broken (Simply Wall Street)
• After a $589K sale, John M. Evans proposes selling 25,000 Beam Therapeutics (BEAM) shares. (Stock Titan)
• PRME Surges 15% After Winning Arbitration Against Beam Clears Path To Human Trials For Its Gene Editing Drug (Stocktwits)

Key terms to know before you follow BEAM

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility